Research
Hormonal
Semaglutide reduced HbA1c by 0.46% of total hemoglobin in SGA-treated patients with schizophrenia, prediabetes, and obesity.
Semaglutide may be an effective treatment option for managing blood glucose levels in this patient population.
StrongSupportsmedium confidence
Semaglutide reduced HbA1c by 0.46% of total hemoglobin (95% CI, -0.56% to -0.36%).
Why this rating
Based on the randomized clinical trial design.
Source
Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity
Ashok Ainkaran Ganeshalingam et al. · JAMA Psychiatry · 2025
DOI 10.1001/jamapsychiatry.2025.2332
rct · n=154Cited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →